Denosumab
Generic name
Denosumab
Brand name
ATC Code
M05BX04
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Bioavailability after subcutaneous administration: 62%
T1/2: mean 28 days (14-55 days)
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Giant cell tumour of bone |
|---|
|
Renal impaiment in children > 3 months
Dose adjustment is not required in renal impairment.
Monitoring of serum calcium concentration is recommended in severe renal impairment (creatinine clearance less than 30 ml / min) and in dialysis due to the increased risk of hypocalcaemia in these patients.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
The side effect profile in children (12-18 years) is similar to the side effect profile in adults. Clinically significant hypercalcaemia after treatment discontinuation has been reported in the post-marketing setting in pediatric patients.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Bisphosphonates | ||
|---|---|---|
| M05BA04 | ||
| M05BA03 | ||
| M05BA07 | ||
| Other drugs affecting bone structure and mineralization | ||
|---|---|---|
| M05BX05 | ||
Reference
- Amgen Europe B.V., SmPC Xgeva (EU/1/11/703/001 -003) 24-03-2020, www.geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
